Section: Contact Information

First Name: Austin
Last Name: Brown
Institution: Baylor College of Medicine
Address 1: 6620 Main Tower
Address 2: 6620 Main Street, Suite 1100D
City: Houston
State/Province/Region: TX
Country: US
Zip/Postal Code: 77030
Phone Number: 7137986634
Alternate Phone Number:
Email Address: austin.brown@bcm.edu

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. Yes
The specific aims are clear and focused. Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. Yes

Project Title: Factors Contributing to Survival Following Second Malignant Neoplasms Diagnosed in Long-term Survivors of Childhood Cancer

Planned research population (eligibility criteria):

Long-term (>5 year) survivors of childhood cancer diagnosed with a second malignant neoplasm

Proposed specific aims:

1. Evaluate the impact of comorbid chronic health conditions on all-cause and cancer-specific mortality following a diagnosis of a second malignant neoplasm among long-term survivors of childhood cancer.

Hypothesis: Prevalent chronic health conditions (any grade 3-5 condition, multiple grade 3-5 conditions, and specific grade 3-5 conditions [e.g., cardiac, endocrine, pulmonary]) will adversely impact survival among long-term survivors of childhood cancer diagnosed with a second malignant neoplasm.

2. Determine the association between frailty phenotypes and all-cause and cancer-specific mortality following a diagnosis of a second malignant neoplasm among long-term survivors of childhood cancer.

Hypothesis: Compared to non-frail childhood cancer survivors, frail and pre-frail survivors will experience poorer overall and cancer-specific survival following a second malignant neoplasm.

3. Identify childhood cancer therapeutic exposures associated with all-cause and cancer-specific mortality following a diagnosis of a second malignant neoplasm among long-
term survivors of childhood cancer.

Hypothesis: Specific therapeutic exposures during childhood (e.g., radiation, alkylating agents, platinum agents, anthracycline) will be associated with a poorer prognosis among survivors diagnosed with second malignant neoplasms.

Will the project require non-CCSS funding to complete? : No

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information : No

Biological samples : No

Medical record data : No

If yes to any of the above, please briefly describe. :

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**

Second Malignancy : Secondary

Chronic Disease : Secondary

Psychology / Neuropsychology : Secondary

Genetics :

Cancer Control : Secondary

Epidemiology / Biostatistics : Primary

**Section: Outcomes or Correlative Factors**

Late mortality : Primary

Second Malignancy : Correlative Factors

**Group: Health Behaviors**

Tobacco :

Alcohol :

Physical activity : Correlative Factors

Medical screening :

Other :

If other, please specify :

**Group: Psychosocial**

Insurance : Correlative Factors

Marriage : Correlative Factors

Education : Correlative Factors

Employment : Correlative Factors

Other :

If other, please specify :

**Group: Medical Conditions**

Hearing/Vision/Speech :

Hormonal systems : Correlative Factors

Heart and vascular : Correlative Factors

Respiratory : Correlative Factors

Digestive : Correlative Factors
Surgical procedures: Correlative Factors
Brain and nervous system: Correlative Factors
Other:
If other, please specify:

**Group: Medications**
Describe medications:

**Group: Psychologic/Quality of Life**
BSI-18:
SF-36: Correlative Factors
CCSS-NCQ:
PTS:
PTG:
Other:
If other, please specify:

**Group: Other**
Pregnancy and offspring:
Family history:
Chronic conditions (CTCAE v3): Correlative Factors
Health status: Correlative Factors

**Group: Demographic**
Age: Correlative Factors
Race: Correlative Factors
Sex: Correlative Factors
Other:
If other, please specify:

**Group: Cancer treatment**
Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**
CCSS Statistical Center:
Local institutional statistician: Yes
If local, please provide the name(s) and contact information of the statistician(s) to be involved.
This project will be conducted in collaboration with Dr. Kiri Ness. Analyses will be conducted under her supervision at St. Jude Children's Research Hospital.
Will this project utilize CCSS biologic samples?: No
If yes, which of the following?:
If other, please explain:

**Section: Other General Comments**
Other General Comments:
Curative childhood cancer therapy places survivors at increased risk of chronic health conditions, frailty, and second primary malignancies (SPMs). Leveraging data from the
Surveillance, Epidemiology, and End Results (SEER) program, we recently compared survival in childhood cancer survivors who developed second primary malignancies (SPMs) to individuals with comparable first primary malignancies (FPMs). Compared with individuals with FPMs, childhood cancer survivors with a similar SPMs experienced poorer OS (HR=1.86, 95% CI: 1.72-2.02) after accounting for age, sex, race, and decade of diagnosis. A history of childhood cancer remained a poor prognostic factor for all specific cancers evaluated, including: breast (HR=2.07, 95% CI: 1.63-2.62), thyroid (HR=3.59, 95% CI: 2.08-6.19), acute myeloid leukemia (HR=2.38, 95% CI: 1.87-3.05), brain (HR=2.09, 95% CI:1.72-2.55), melanoma (HR=2.57, 95% CI: 1.55-4.27), bone (HR=1.88, 95% CI:1.37-2.57), and soft tissue sarcoma (HR=2.44, 95% CI: 1.78-3.33). The objective of this CCSS proposal is to evaluate whether chronic health conditions, frailty, or specific childhood therapeutic exposures are associated with inferior outcomes among childhood cancer survivors diagnosed with SPMs.

I agree to share this information with St. Jude: Yes